Use of a clinician-facing dashboard combined with a best practice alert helped increase rates of HLA-B*58:01 genetic testing among patients prescribed allopurinol.

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase ...

Patients with HER2-positive breast cancer in the FLAMINGO-01 phase 3 clinical trial are seeing a continued reduction in recurrence rates, Greenwich LifeSciences, Inc. has reported. The preliminary ...

A hidden donor-recipient HLA mismatch may increase the risk of life-threatening immune complications after cord blood ...

With Human Rights Day upon us, South Africa reflects on the promise of life for every citizen. The pressing need for registered stem cell donors reminds us that lives hinge on collective action — ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the 'Company'), a clinical-stage biopharmaceutical company focused on its Phase ...

CareDx (NASDAQ:CDNA) executives outlined the company’s transplant-focused strategy, recent financial performance, and 2026 ...

Immatics N.V. remains a speculative Buy, driven by progress with anzu-cel in 2L melanoma and a robust cell therapy pipeline.

Pune: To raise awareness about thalassaemia and provide life-saving treatment opportunities for affected children, a free bone marrow cross-matching camp will be held at the District Hospital in Aundh ...

CareDx reported strong Q4 2025 revenue growth of 25% year-over-year, reaching $108 million. The company is expanding its Transplant+ strategy to include hematologic cancers with the AlloHeme test.

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the 'Company'), a clinical-stage biopharmaceutical company focused on its Phase ...

Eledon Pharmaceuticals, Inc. is rated a Strong Buy following positive phase 2 BESTOW results for tegoprubart. Read more on ...